In addition, immunophenotypic and transcriptional profiling was performed via multicolor FACS and scRNA-seq of CD34+ HSPCs mobilized on the GENESIS trial, as well as a contemporaneous, prospectively enrolled cohort of demographically similar patients with MM mobilized with plerixafor + G-CSF (protocol no. 201103349) and three cohorts of healthy, allogeneic HSPC donors (allo-donors) undergoing single-agent mobilization with motixafortide, plerixafor or G-CSF alone (NCT02639559, NCT00241358, protocol no. 201106261, respectively). This evidence concerns the gene CSF3 and Miyoshi myopathy.